Name: DERMAJET
Brand: DERMAJET

Precision Microneedling System DERMAJET

A microneedling platform for skin regeneration and transdermal delivery of biologics.

Request info Technology

CEEuropean conformity

RoHSRestricted substances

12 hBattery operation

Dual-action paradigm

Two effects are produced by a single pass: a physiological wound-healing response, and micro-channels that carry molecules past the barrier.

Action 01

Percutaneous collagen induction

Non-ablative physical micro-injury preserves the stratum corneum while triggering the physiological wound-healing cascade.

Action 02

Bypassing the 500 Dalton rule

Precise micro-channels are formed for the targeted delivery of high-molecular-weight biological preparations.

Platform hardware

Safe and fast

Automated high-speed precision puncture reduces epidermal tearing compared with a manual roller.

Integrated delivery

A sterile ampoule system designed for direct, uncontaminated injection of the serum.

Mobility

Lightweight and easy to carry, powered by a lithium-ion battery for up to 12 hours of continuous operation.

Mechanism of action

Breaking through the barrier function, in four stages.

Needles penetrating the epidermis while the stratum corneum is preserved — Step 01Micro-injuryThe needles penetrate the epidermis while preserving the stratum corneum.

Active ingredients delivered transdermally into the dermal layer — Step 02DeliveryActive ingredients are delivered transdermally and directly into the dermal layer.

Fibroblast proliferation and neocollagenesis in the deep dermis — Step 03ActivationFibroblast proliferation and neocollagenesis are induced in the deep dermis.

Remodelled skin surface with a smooth appearance — Step 04RegenerationThe skin surface is remodelled and regenerates into a smoother, revitalised state.

Comparison of resurfacing modalities

How mechanical microneedling differs from thermal and chemical resurfacing.

Clinical parameter DERMAJET (MTS) Fractional laser Deep chemical peel

Stratum corneum integrity Preserved Ablation / damage Destruction

PIH risk Very low · reported safe for Fitzpatrick IV–VI High High

Downtime 1–3 days 5–7 days 7–14 days

By avoiding thermal heat and chemical burns, DERMAJET aims at deep dermal remodeling without triggering an inflammatory pigment response.

Clinical indications

Five areas, each with a recommended combination protocol.

Indication I

Atrophic and hypertrophic acne scars

Precision microneedles mechanically break down rigid scar tissue, promoting type I collagen production and aligned elastin deposition. The result is scar elevation, smoother texture and restored dermal volume.

Recommended combinationPRP or PMMA-collagen gel

Indication II

Melasma and pigmentary disorders

Thermal energy can over-stimulate hyperactive melanocytes and provoke severe PIH in melasma patients. The approach here is to normalise cell function and repair basement-membrane damage without thermal injury.

Recommended combinationTranexamic acid or exosomes

Indication III

Skin ageing, laxity and wrinkles

A flattened dermal-epidermal junction with solar elastosis is targeted for a firmer junction and higher skin density, with improvement of solar elastosis, tightening of enlarged pores and recovery of structural elasticity.

Recommended combinationBotulinum toxin type A (microtox) or hyaluronic acid

Indication IV

Alopecia and scalp regeneration

Three points of action: micro-injury raises transdermal absorption of topical repair agents, mechanical stimulus induces local growth-factor production, and angiogenesis supplies nutrients to the follicle.

Recommended combinationMinoxidil, PRP or targeted exosomes

Indication V

Inflammatory skin disease

For psoriasis, direct transdermal delivery of methotrexate reduces scaly plaques while avoiding systemic side effects. For atopic dermatitis, painless transdermal delivery of triamcinolone or regulatory T cells suppresses the overactive Th2 response.

Recommended combinationTriamcinolone acetonide

Note

Prescription-only agents

Methotrexate, triamcinolone, botulinum toxin, minoxidil and PRP are prescription-only or medically controlled in most jurisdictions. Their use, and the scope of any procedure, is decided by a licensed practitioner under the regulations of the country concerned.

Transdermal synergy

Agents suited to delivery through the micro-channels.

Exosome

Cell-to-cell communication

Source: damask rose stem cells or human adipose tissue. Cargo: miRNA, nine growth factors, thirty amino acids and peptides. Action: intercellular communication for deep tissue repair and pigment control.

PDRN

Polydeoxyribonucleotide

Source: salmon sperm DNA fragments. Action: activation of the A2A adenosine receptor to promote fibroblast activity and accelerate wound healing.

TA & Vitamin C

Targeted depigmentation

Target: melasma and vascular pigmentation. Mechanism: antiplasmin action and direct inhibition of melanin synthesis.

Hyaluronic acid

Barrier and hydration

Target: barrier recovery and xerosis. Mechanism: deep dermal hydration and immediate structural plumping.

PRP

Platelet-rich plasma

Target: severe atrophic scars and alopecia. Mechanism: large-scale neocollagenesis driven by autologous growth factors.

Matrix

Combination overview

Each indication is paired with a primary biological target and a preferred transdermal agent, summarised in the table below.

IndicationPrimary biological targetPreferred transdermal agent

Acne scarsBreakdown of fibrous tissue and volume recoveryPRP / PMMA-collagen

MelasmaMelanocyte controlExosomes + tranexamic acid

Skin ageing and laxityImmune modulationPDRN (salmon DNA) + HA

AlopeciaAngiogenesisMinoxidil + growth factors

Atopic dermatitisReinforcement of the dermal-epidermal junctionTriamcinolone acetonide

Safety, compliance and recovery

The closure timeline for the micro-channels created during treatment.

T = 0Delivery of high-molecular-weight substances, past the 500 Dalton barrier.

T = 1 hourClosure of the natural micropores is complete and the external infection risk is resolved.

T = 24–72 hoursFull social recovery, with mild erythema resolving.

Patient tolerability is higher than conventional syringe injection, and the unpredictable necrosis risk associated with deep dermal fillers does not apply.

References

These sources concern microneedling as a modality and are not clinical trials of this device.

01Agrawal et al. (2020). Microneedles: An advancement to transdermal drug delivery system approach. Journal of Applied Pharmaceutical Science

02Vora, L.K. et al. (2023). Long-acting microneedle formulations. Advanced Drug Delivery Reviews

03Jaiswal, S. et al. (2024). Microneedling in Dermatology: A Comprehensive Review of Applications, Techniques, and Outcomes. Cureus

04Li, H. et al. (2024). Comparing the efficacy and safety of microneedling and its combination with other treatments in patients with acne scars. Archives of Dermatological Research

05Shen, Y.C. et al. (2022). Microneedling Monotherapy for Acne Scar: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Aesthetic Plastic Surgery

06Proietti, I. et al. (2024). Efficacy and Tolerability of a Microneedling Device Plus Exosomes for Treating Melasma. Applied Sciences

07Suh, D.H. et al. (2020). Monopolar Radiofrequency Treatment for Facial Laxity: Histometric Analysis. Journal of Cosmetic Dermatology

08Wu, C. et al. (2024). Microneedles as transdermal drug delivery system for enhancing skin disease treatment. Acta Pharmaceutica Sinica B

09Chen, J. et al. (2022). Microneedle-mediated drug delivery for cutaneous disease. Frontiers in Bioengineering and Biotechnology

10El Attar, Y. et al. (2022). Efficacy and Safety of Tranexamic Acid Versus Vitamin C After Microneedling. Journal of Cosmetic Dermatology

11Nguyen, H.X. & Nguyen, C.N. (2023). Microneedle-Mediated Transdermal Delivery of Biopharmaceuticals. Pharmaceutics

12Bos, J.D. & Meinardi, M.M. (2000). The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology

13Controlled Clinical Trial Evaluating the Efficacy of Microneedling Combined with Exosomes Versus Microneedling Alone (2025). Preprints.org

14Wang, X. et al. (2024). Advances in biomedical systems based on microneedles: design, fabrication, and application. Academic Anchor

Reference 07 concerns monopolar radiofrequency, cited here for histometric analysis of facial laxity rather than microneedling. Bibliographic details should be verified against the original publications before use in regulated materials.

Start a distribution enquiry

A representative will take you through demonstration scheduling, supply terms, certification documents and the training programme. Telling us your market and existing equipment speeds the process up.

Request info

Enquiries answered on business days. Availability of on-site demonstrations varies by region.

Language